Apellis Pharmaceuticals

$47.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-0.52%) Today
$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell APLS and other stocks, options, and ETFs commission-free!

About APLS

Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA. The listed name for APLS is Apellis Pharmaceuticals, Inc. Common Stock.

CEO
Cedric Francois
Employees
235
Headquarters
Waltham, Massachusetts
Founded
2009
Market Cap
3.61B
Price-Earnings Ratio
Dividend Yield
Average Volume
794.13K
High Today
$49.42
Low Today
$46.86
Open Price
$48.34
Volume
722.58K
52 Week High
$49.42
52 Week Low
$16.85

Collections

APLS Earnings

-$2.29
-$1.53
-$0.76
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, Pre-Market

You May Also Like